Orexigen soars on CV data that FDA didn't want released
This article was originally published in Scrip
Orexigen Therapeutics soared 32% to close at $7.64 per share on 3 March after the San Diego-based company disclosed a newly issued patent for its weight loss drug Contrave (naltrexone and bupropion) that contained positive interim results from a cardiovascular outcomes trial (CVOT) known as the Light study – data that the US FDA expressly asked Orexigen not to disclose.
You may also be interested in...
Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.